These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 20067122

  • 21. Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate.
    Thorburn CE, Molesworth SJ, Sutherland R, Rittenhouse S.
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2796-801. PubMed ID: 9124843
    [Abstract] [Full Text] [Related]

  • 22. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
    London N, Thomson CJ, Amyes SG, Stobberingh E.
    FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670
    [Abstract] [Full Text] [Related]

  • 23. Evidence for a true post-beta-lactamase-inhibitor effect of clavulanic acid against Klebsiella pneumoniae and Haemophilus influenzae.
    Murbach V, Dhoyen N, Linger L, Monteil H, Jehl F.
    Clin Microbiol Infect; 2001 Dec; 7(12):661-5. PubMed ID: 11843906
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of beta-lactam and inhibitor combinations in a diffusion chamber model in rabbits.
    Georgopoulos A, Buxbaum A, Graninger W.
    J Antimicrob Chemother; 1999 Apr; 43(4):497-501. PubMed ID: 10350378
    [Abstract] [Full Text] [Related]

  • 25. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    Liu Q, Rand K, Derendorf H.
    Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
    [Abstract] [Full Text] [Related]

  • 26. Killing of Escherichia coli by beta-lactams at different inocula.
    Tam VH, Ledesma KR, Chang KT, Wang TY, Quinn JP.
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):166-71. PubMed ID: 19304437
    [Abstract] [Full Text] [Related]

  • 27. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
    Robin F, Krebs M, Delmas J, Gibold L, Mirande C, Bonnet R.
    J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211
    [Abstract] [Full Text] [Related]

  • 28. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC, Hsu LY, Luh KT, Hsieh WC.
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [Abstract] [Full Text] [Related]

  • 29. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
    Lister PD, Prevan AM, Sanders CC.
    Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
    [Abstract] [Full Text] [Related]

  • 30. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J, Livne G, Ashkenazi S, Levy I, Pitlik S, Ofir O, Lev B, Samra Z.
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [Abstract] [Full Text] [Related]

  • 31. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D, Yinnon AM, Broide E, Rudensky B.
    Chemotherapy; 2007 May; 53(3):185-9. PubMed ID: 17347564
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
    VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2809-14. PubMed ID: 23629705
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Bacterial growth delay in E. coli: demonstration and evaluation of the beta-lactamase post-inhibitor effect on 6 strains with different resistance phenotypes].
    Murbach V, Bronner S, Dhoyen N, Sougakoff W, Monteil H, Jehl F.
    Pathol Biol (Paris); 2000 Jun; 48(5):478-84. PubMed ID: 10949845
    [Abstract] [Full Text] [Related]

  • 36. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC, Fiorenza MA, Estrada SJ.
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [Abstract] [Full Text] [Related]

  • 37. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD, Le P, Church DL, Gregson DB, Laupland KB.
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [Abstract] [Full Text] [Related]

  • 38. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
    Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
    [No Abstract] [Full Text] [Related]

  • 39. Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
    Fujita A, Kimura K, Yokoyama S, Jin W, Wachino J, Yamada K, Suematsu H, Yamagishi Y, Mikamo H, Arakawa Y.
    PLoS One; 2015 Nov; 10(11):e0142366. PubMed ID: 26539828
    [Abstract] [Full Text] [Related]

  • 40. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.
    Livermore DM, Mushtaq S, Ge Y.
    J Antimicrob Chemother; 2010 Sep; 65(9):1972-4. PubMed ID: 20595207
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.